Intellia Therapeutics, a clinical-stage genome editing company, completed the acquisition of Rewrite Therapeutics, a private biotechnology company, from venture capital firms Civilization Ventures and Prefix Capital, for $200m. “At Intellia, we have built the industry’s broadest and deepest genome editing platform by staying at the forefront of new techniques, while also extending the capabilities of CRISPR/Cas9 editing to make precisely targeted changes to DNA. We could not be more excited to add Rewrite’s additional capabilities to our growing platform, offering us new possibilities and the potential to target diseases beyond those currently being explored in our pipeline," John Leonard, Intellia President and CEO.